KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2016 - 2025)

Jazz Pharmaceuticals has reported Capital Expenditures over the past 16 years, most recently at $816.0 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $816.0 million for Q4 2025, up 3392.7% from a year ago — trailing twelve months through Dec 2025 was $858.1 million (changed N/A YoY), and the annual figure for FY2025 was $858.1 million, changed.
  • Capital Expenditures for Q4 2025 was $816.0 million at Jazz Pharmaceuticals, up from -$816.0 million in the prior quarter.
  • Over the last five years, Capital Expenditures for JAZZ hit a ceiling of $844.2 million in Q2 2025 and a floor of -$816.0 million in Q3 2025.
  • Median Capital Expenditures over the past 5 years was $7.1 million (2021), compared with a mean of $45.7 million.
  • Peak annual rise in Capital Expenditures hit 11804.84% in 2025, while the deepest fall reached 7664.24% in 2025.
  • Jazz Pharmaceuticals' Capital Expenditures stood at $10.0 million in 2021, then decreased by 5.91% to $9.4 million in 2022, then crashed by 247.79% to -$13.9 million in 2023, then plummeted by 78.81% to -$24.8 million in 2024, then skyrocketed by 3392.7% to $816.0 million in 2025.
  • The last three reported values for Capital Expenditures were $816.0 million (Q4 2025), -$816.0 million (Q3 2025), and $844.2 million (Q2 2025) per Business Quant data.